| 【英語タイトル】Global Female Infertility Treatment Drugs Market Size study & Forecast, by Therapy( Gonadotropins, Clomiphene, Letrozole, Metformin , Leuprolide Acetate and Others) by Route of Administration( Oral and Injectable), by Distribution Channel ( Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies) and Regional Analysis, 2022-2029
|
 | ・商品コード：BZW23MR088
・発行会社（調査会社）：Bizwit Research & Consulting
・発行日：2023年3月6日
・ページ数：約200
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野：医療
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
❖ レポートの概要 ❖
Bizwit Research社の本調査レポートは、2021年に2,649.8百万ドルであった世界の女性用不妊治療薬市場規模が、2022年から2029年の間に4.3%成長すると予想しています。本レポートでは、女性用不妊治療薬の世界市場について調査し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、治療法別（ゴナドトロピン、クロミフェン、レトロゾール、メトホルミン、その他）分析、投与方法別（経口、注射）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争状況、調査プロセスなどの項目を掲載しています。また、本書には、Ferring Pharmaceuticals、Merck & Co, Inc.、Bayer AG、Abbott Laboratories、Par Pharmaceuticals、Sumitovant、Livzon、Zydus Cadila、Mankind Pharma、Oxolifeなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界の女性用不妊治療薬市場規模：治療別
- ゴナドトロピンの市場規模
- クロミフェンの市場規模
- レトロゾールの市場規模
- メトホルミンの市場規模
- その他治療の市場規模
・世界の女性用不妊治療薬市場規模：投与方法別
- 経口投与における市場規模
- 注射投与における市場規模
・世界の女性用不妊治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の女性用不妊治療薬市場規模：地域別
- 北米の女性用不妊治療薬市場規模
- ヨーロッパの女性用不妊治療薬市場規模
- アジア太平洋の女性用不妊治療薬市場規模
- 中南米の女性用不妊治療薬市場規模
- その他地域の女性用不妊治療薬市場規模
・競争状況
・調査プロセス |
Global Female Infertility Treatment Drugs Market is valued approximately USD 2,649.8 million in 2021 and is anticipated to grow with a healthy growth rate of more than 4.3% over the forecast period 2022-2029. Female infertility is a condition where a woman is unable to conceive. Female infertility can be caused by several variables, including age, hormonal imbalance, physical health, and lifestyle choices. A few of the tests used to identify female infertility include ovarian reserve testing, hysterosalpingography, and ovulation testing. The Female Infertility Treatment Drugs market is expanding because of factors such as increasing infertility rates globally and increasing funding for infertility R&D. However, the presence of effective alternatives to medication, high cost of drugs may halt market growth.
Decline in prevalence of fertility rates across the globe is fostering the market growth. For instance, according to the World Bank Organisation, the total fertility rate (births per woman) was 2.427 in 2017, which was further decreased to 2.402 in 2019, globally. Thus these decline indicates the rise in infertility rates which is driving the marker growth. Furthermore, Governments worldwide to support to infertility patients by providing insurance coverage for treatment and rise in drug development activities is creating a lucrative growth to the market.
The key regions considered for the Global Female Infertility Treatment Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region’s increasing infertility rate. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for drug development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.
Major market player included in this report are:
Ferring Pharmaceuticals
Merck & Co, Inc.
Bayer AG
Abbott Laboratories
Par Pharmaceuticals
Sumitovant
Livzon
Zydus Cadila
Mankind Pharma
Oxolife
Recent Developments in the Market:
In January 2020, Bayer AG announced a new five-year, multi-target collaboration with Evotec SE, a biotechnology company specialising in women’s health, to develop a number of clinical candidates for the treatment of polycystic ovarian syndrome (PCOS), one of the factors contributing to female infertility.
In January 2019, Ferring Pharmaceuticals, a biopharmaceutical company, signed an exclusive agreement with Sun Pharmaceutical Industries Ltd., an Indian multinational pharmaceutical company, to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate Injection, which is used to treat female infertility.
Global Female Infertility Treatment Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Therapy, Route of Administration, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Therapyofferings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapy:
Gonadotropins
Clomiphene
Letrozole
Metformin
Leuprolide Acetate
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
1.2.1. Female Infertility Treatment Drugs Market, by Region, 2019-2029 (USD Million)
1.2.2. Female Infertility Treatment Drugs Market, by Therapy, 2019-2029 (USD Million)
1.2.3. Female Infertility Treatment Drugs Market, by Route of Administration, 2019-2029 (USD Million)
1.2.4. Female Infertility Treatment Drugs Market, by Distribution Channel, 2019-2029 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Female Infertility Treatment Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Female Infertility Treatment Drugs Market Dynamics
3.1. Female Infertility Treatment Drugs Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing infertility rates globally
3.1.1.2. Increasing funding for infertility R&D
3.1.2. Market Challenges
3.1.2.1. The presence of effective alternatives to medications
3.1.2.2. High cost of Drugs
3.1.3. Market Opportunities
3.1.3.1. Governments worldwide to support to infertility patients by providing insurance coverage for treatment.
3.1.3.2. Rise in drug development activities
Chapter 4. Global Female Infertility Treatment Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Female Infertility Treatment Drugs Market, by Therapy
6.1. Market Snapshot
6.2. Global Female Infertility Treatment Drugs Market by Therapy, Performance – Potential Analysis
6.3. Global Female Infertility Treatment Drugs Market Estimates & Forecasts by Therapy 2019-2029 (USD Million)
6.4. Female Infertility Treatment Drugs Market, Sub Segment Analysis
6.4.1. Gonadotropins
6.4.2. Clomiphene
6.4.3. Letrozole
6.4.4. Metformin
6.4.5. Leuprolide Acetate
6.4.6. Others
Chapter 7. Global Female Infertility Treatment Drugs Market, by Route of Administration
7.1. Market Snapshot
7.2. Global Female Infertility Treatment Drugs Market by Route of Administration, Performance – Potential Analysis
7.3. Global Female Infertility Treatment Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Million)
7.4. Female Infertility Treatment Drugs Market, Sub Segment Analysis
7.4.1. Oral
7.4.2. Injectable
Chapter 8. Global Female Infertility Treatment Drugs Market, by Distribution Channel
8.1. Market Snapshot
8.2. Global Female Infertility Treatment Drugs Market by Distribution Channel, Performance – Potential Analysis
8.3. Global Female Infertility Treatment Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Million)
8.4. Female Infertility Treatment Drugs Market, Sub Segment Analysis
8.4.1. Hospitals Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
Chapter 9. Global Female Infertility Treatment Drugs Market, Regional Analysis
9.1. Female Infertility Treatment Drugs Market, Regional Market Snapshot
9.2. North America Female Infertility Treatment Drugs Market
9.2.1. U.S. Female Infertility Treatment Drugs Market
9.2.1.1. Therapy breakdown estimates & forecasts, 2019-2029
9.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Female Infertility Treatment Drugs Market
9.3. Europe Female Infertility Treatment Drugs Market Snapshot
9.3.1. U.K. Female Infertility Treatment Drugs Market
9.3.2. Germany Female Infertility Treatment Drugs Market
9.3.3. France Female Infertility Treatment Drugs Market
9.3.4. Spain Female Infertility Treatment Drugs Market
9.3.5. Italy Female Infertility Treatment Drugs Market
9.3.6. Rest of Europe Female Infertility Treatment Drugs Market
9.4. Asia-Pacific Female Infertility Treatment Drugs Market Snapshot
9.4.1. China Female Infertility Treatment Drugs Market
9.4.2. India Female Infertility Treatment Drugs Market
9.4.3. Japan Female Infertility Treatment Drugs Market
9.4.4. Australia Female Infertility Treatment Drugs Market
9.4.5. South Korea Female Infertility Treatment Drugs Market
9.4.6. Rest of Asia Pacific Female Infertility Treatment Drugs Market
9.5. Latin America Female Infertility Treatment Drugs Market Snapshot
9.5.1. Brazil Female Infertility Treatment Drugs Market
9.5.2. Mexico Female Infertility Treatment Drugs Market
9.5.3. Rest of Latin America Female Infertility Treatment Drugs Market
9.6. Rest of The World Female Infertility Treatment Drugs Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Ferring Pharmaceuticals
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Merck & Co, Inc.
10.2.3. Bayer AG
10.2.4. Abbott Laboratories
10.2.5. Par Pharmaceuticals
10.2.6. Sumitovant
10.2.7. Livzon
10.2.8. Zydus Cadila
10.2.9. Mankind Pharma
10.2.10. Oxolife
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
